Welcome to our dedicated page for Veri MedTech Holdings SEC filings (Ticker: VRHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Veri MedTech Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Veri MedTech Holdings's regulatory disclosures and financial reporting.
Veri Medtech Holdings, Inc. is conducting a firm commitment public offering of 3,750,000 shares of common stock at $4.00 per share, for gross proceeds of $15,000,000. After underwriting discounts and estimated expenses, net proceeds are expected to be about $13,350,000, to fund organic and acquisitive growth.
The stock currently trades on the OTC market under “VRHI”; the deal will not close unless Nasdaq Capital Market listing is approved. After the offering, 23,750,003 common shares will be outstanding, while Series A preferred stock gives executives 80% of voting power, making the company a controlled company. Veri Medtech, through Veriheal, sells medical marijuana card services across many U.S. states, generating 2025 revenue of about $11 million but with a $2.32 million net loss and a going concern warning due to deficits and ongoing losses.
Veri Medtech Holdings, Inc. is conducting a firm commitment public offering of 3,750,000 shares of common stock at $4.00 per share. This implies gross proceeds of $15.0 million, with estimated net proceeds of about $13.35 million after $1.5 million in underwriting discounts and $150,000 of offering expenses.
The company currently has 20,000,003 common shares outstanding and expects 23,750,003 shares outstanding after the offering, excluding any exercise of a 562,500-share over-allotment option. Veri Medtech’s stock trades on the OTC Market under “VRHI,” and the company intends to list on the NASDAQ Capital Market under the same symbol; the offering will not close if the listing is not approved.
Veri Medtech operates a healthcare technology platform focused on medical marijuana card concierge services through subsidiaries, generating revenues of approximately $11 million in 2025 but incurring a net loss of about $2.32 million. The company’s auditors highlight substantial doubt about its ability to continue as a going concern due to shareholders’ deficit and continued losses, so it plans to use offering proceeds for organic and acquisitive growth and general corporate purposes.
Veri Medtech Holdings, Inc. is conducting a firm-commitment primary offering of 3,750,000 shares of Common Stock at $4.00 per share, for gross proceeds of $15,000,000. After underwriting discounts of $1,500,000 and $150,000 of offering expenses, the company expects net proceeds of $13,350,000 to fund organic and acquisitive growth and other uses described in the prospectus.
Shares outstanding are expected to increase from 20,000,003 to 23,750,003, excluding any exercise of the 45‑day over-allotment option for up to 562,500 additional shares. The underwriter will also receive warrants to purchase 300,000 shares at an exercise price of $4.40.
Veri Medtech is a holding company whose main subsidiary Veriheal operates a healthcare technology platform that connects patients with physicians for medical marijuana card services, generating approximately $11 million and $17 million of revenue in 2025 and 2024, respectively. The company reported net losses of about $2,320,000 in 2025 and $409,000 in 2024 and discloses substantial doubt about its ability to continue as a going concern due to stockholders’ deficit, accumulated deficit and working capital deficit.
Veri Medtech qualifies as an emerging growth company and smaller reporting company and intends to list its Common Stock on the Nasdaq Capital Market under the symbol “VRHI”; the offering will not close if the listing is not approved. Following the offering, executives will control more than 50% of voting power, but the company states it will follow Nasdaq’s standard corporate governance practices rather than rely on controlled company exemptions.
Veri Medtech Holdings, Inc. is pursuing a primary firm commitment public offering of common stock to move its listing from the OTC market to the NYSE American, with net proceeds intended for organic and acquisitive growth. The company operates a healthcare technology platform, primarily through subsidiary Veriheal, that helps patients obtain medical marijuana cards and related consultations across numerous U.S. states. Veri Medtech generated approximately $22 million in revenue in 2023 and $17 million in 2024, shifting from about $3.53 million of net income in 2023 to a net loss of roughly $409,000 in 2024. As of December 31, 2024 and September 30, 2025, it reported shareholders’ and working capital deficits and recent net losses, and its auditors highlight substantial doubt about its ability to continue as a going concern without additional capital.